Abstract
The combination of traditional disease modifying antirheumatic drugs such as methotrexate (MTX) with biologic agents for treating rheumatoid arthritis (RA) has thus far been limited. The combination of MTX and a depleting anti-CD4 monoclonal antibody (cM-T412) has been evaluated in phase I and II trials in patients with refractory RA. The potential of combining MTX with other biologic agents is reviewed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal / therapeutic use*
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / therapy*
-
CD4 Antigens / immunology*
-
Humans
-
Immunotherapy*
-
Methotrexate / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
CD4 Antigens
-
Methotrexate